Dr Reddy's Lab completes Phase 1 study of proposed arthritis drug
The company further said it is initiating a global Phase III study to compare the efficacy, safety, tolerability and immunogenicity of 'DRL_TC' with the reference product in patients with moderate-to-severe active rheumatoid arthritis.
Dr Reddy's is developing the proposed Tocilizumab biosimilar as both subcutaneous and intravenous formulations. (Representative image form Reuters)